Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration ...

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible ...

During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in ...

A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...

The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer. The FDA approved osimertinib (Tagrisso) for the treatment of adults with locally ...

Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma ...